Unstructured EHR Data Expands Cohort Identification by 1,500%
When a biopharma manufacturer began developing a new therapy to treat a rare disease, its leadership team realized that finding diagnosed patients would be a challenge. The company wanted to conduct feasibility research on the indication to map the patient journey, identify patients with a specific subtype, and quantify the patient population that would potentially […]
Powering Unbiased Outcomes Research with Longitudinal Data
In preparation for a new launch, a medical device company needed to conduct a health economics and outcomes research (HEOR) study on cemented and uncemented knee arthroplasties. The company wanted to know if readmission and infection rates differed for arthroplasty patients depending on the fixation method used. By conducting this research, the company hoped to […]
Complex Cohort Identification Fuels Real-Time HCP Targeting
A large manufacturer preparing for the launch of its new oncology therapy sought a deeper understanding of the specific disease state. The company’s market access team wanted to track specialist referral patterns and determine the average time between diagnosis and treatment. The manufacturer also needed to identify patients who were potentially eligible for its product, […]
Unlocking Value Potential for a Client’s Rare Disease Treatment
A pharmaceutical manufacturer faced challenges in identifying patients early in the treatment journey for a rare disease, aiming to improve its medication uptake. The client was aiming to: Identify new revenue opportunities by uncovering untreated patient populations Tackle healthcare access disparities affecting underserved groups Optimize provider engagement and reimbursement strategies
Harnessing the Power of RWE to Improve Drug Development
Real-world evidence (RWE) is becoming increasingly important in driving pharmaceutical innovations, as it helps researchers to understand the settings in which a drug, medical device, or other treatment is applied, such as innovation, care patterns, and disease burden in populations. Through the systematic analysis of real-world data (RWD), RWE can support clinical trial evidence, particularly […]
Addressing Cost Barriers and Enhancing Medicare Access Strategies to Improve Commercialization Strategy
A pharmaceutical manufacturer sought to enhance their product’s commercialization strategy by analyzing patient profiles, the market access landscape, and competitive dynamics. The client was aiming to: Refine its market access strategy to address affordability challenges Identify unmet needs in the treatment landscape for recurrent infections
Harnessing Lab Data to Speed Time to Treatment
In recent years, pharma companies have begun to embrace lab data as a richly rewarding dataset for a whole host of purposes, including trial enrollment and site identification, patient monitoring and disease progression, and commercial targeting and market access insights. Along with test orders, values, and results, deidentified lab data includes a wealth of information, […]
How Real-World Evidence is Impacting Regulatory Decision-Making: A Collection of 10 Recent Regulatory Decisions Based on RWE
Volume 3 Discover the power of real-world evidence (RWE) in shaping regulatory decisions through “How RWE is Impacting Regulatory Decision-Making.” Volume 3 of Panalgo’s popular use cases series reveals 10 recent instances where life sciences companies have not only invested in RWE but have successfully utilized it in their submissions to the FDA and other […]
How Real-World Evidence is Impacting Regulatory Decision-Making: 12 Recent Approvals Based on RWE
Volume 2 Offering 12 new use cases of life sciences companies continuing to invest in RWD to advance product approvals before an FDA that is only becoming more accepting of RWE.
Improving Market Access: Are You Making the Most of Real-World Data?
As drug and therapy innovation becomes more specialized and costs continue to rise, improving market access becomes more complicated. As the landscape evolves, pharma manufacturers must strategize accordingly to ensure a successful launch. Navigating the changing market access landscape is a common struggle for pharma manufacturers: One study found that 50% of all pharma manufacturers […]
